Mucins and Tight Junctions are Severely Altered in Necrotizing Enterocolitis Neonates

Abstract

Objective This study investigates the expression levels of mucin 1 (MUC1), MUC2, occludin, and zonula occludens-1 (ZO-1) in necrotizing enterocolitis (NEC).

Study Design Intestinal specimens of surgical patients suffering from NEC (the NEC group) and intestinal specimens of patients with congenital intestinal atresia (the control group) were collected. Immunohistochemical changes in MUC1, MUC2, occludin, and ZO-1 were compared between the two groups.

Results Our study showed a significant decrease in the expression levels of MUC1 (p = 0.004), MUC2 (p = 0.001), occludin (p = 0.004), and ZO-1 (p = 0.013) in neonates suffering from NEC as compared with the control group.

Conclusion Mucins and tight junctions are severely altered in NEC neonates. This finding might provide clues for rupture of the intestinal barrier. Further research is needed to investigate the gene expression as well as the exact mechanisms behind these changes. This will help us better understand the role of the intestinal barrier in NEC.

Key Points

• Mucins and tight junctions are severely altered in NEC neonates.

• We first demonstrate that the expression levels of MUC1are obviously reduced in neonates suffering from NEC.

• Expression levels of MUC2, occludin, and ZO-1, are also significantly decreased in neonates suffering from NEC.

Keywords

NEC - MUC1 - MUC2 - ZO-1 - occluding - intestinal barrier

Publication History

Received: 19 February 2020

Accepted: 13 April 2020

Article published online:
23 May 2020

• References

• 1 Moore SA, Nighot P, Reyes C. et al. Intestinal barrier dysfunction in human necrotizing enterocolitis. J Pediatr Surg 2016; 51 (12) 1907-1913
• 2 Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med 2011; 364 (03) 255-264
• 3 Halpern MD, Denning PW. The role of intestinal epithelial barrier function in the development of NEC. Tissue Barriers 2015; 3 (1-2): e1000707
• 4 Niño DF, Sodhi CP, Hackam DJ. Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nat Rev Gastroenterol Hepatol 2016; 13 (10) 590-600
• 5 Dhar P, McAuley J. The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation. Front Cell Infect Microbiol 2019; 9: 117
• 6 Ballester B, Milara J, Cortijo J. Mucins as a new frontier in pulmonary fibrosis. J Clin Med 2019; 8 (09) E1447
• 7 Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol 2017; 11 (09) 821-834
• 8 Syrkina MS, Rubtsov MA. MUC1 in cancer immunotherapy - new hope or phantom menace?. Biochemistry (Mosc) 2019; 84 (07) 773-781
• 9 Lindén SK, Sheng YH, Every AL. et al. MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog 2009; 5 (10) e1000617
• 10 Reynolds IS, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Burke JP. Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers. Cancer Metastasis Rev 2019; 38 (1-2): 237-257
• 11 Ng GZ, Menheniott TR, Every AL. et al. The MUC1 mucin protects against Helicobacter pylori pathogenesis in mice by regulation of the NLRP3 inflammasome. Gut 2016; 65 (07) 1087-1099
• 12 Ng GZ, Sutton P. The MUC1 mucin specifically inhibits activation of the NLRP3 inflammasome. Genes Immun 2016; 17 (03) 203-206
• 13 Li B, Hock A, Wu RY. et al. Bovine milk-derived exosomes enhance goblet cell activity and prevent the development of experimental necrotizing enterocolitis. PLoS One 2019; 14 (01) e0211431
• 14 Jing Y, Peng F, Shan Y, Jiang J. Berberine reduces the occurrence of neonatal necrotizing enterocolitis by reducing the inflammatory response. Exp Ther Med 2018; 16 (06) 5280-5285
• 15 Wu RY, Li B, Koike Y. et al. Human milk oligosaccharides increase mucin expression in experimental necrotizing enterocolitis. Mol Nutr Food Res 2019; 63 (03) e1800658
• 16 Clark JA, Doelle SM, Halpern MD. et al. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. Am J Physiol Gastrointest Liver Physiol 2006; 291 (05) G938-G949
• 17 Tian F, Liu GR, Li N, Yuan G. Insulin-like growth factor I reduces the occurrence of necrotizing enterocolitis by reducing inflammatory response and protecting intestinal mucosal barrier in neonatal rats model. Eur Rev Med Pharmacol Sci 2017; 21 (20) 4711-4719
• 18 Coursodon-Boyiddle CF, Snarrenberg CL, Adkins-Rieck CK. et al. Pomegranate seed oil reduces intestinal damage in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2012; 303 (06) G744-G751
• 19 Puiman PJ, Jensen M, Stoll B. et al. Intestinal threonine utilization for protein and mucin synthesis is decreased in formula-fed preterm pigs. J Nutr 2011; 141 (07) 1306-1311
• 20 Bein A, Eventov-Friedman S, Arbell D, Schwartz B. Intestinal tight junctions are severely altered in NEC preterm neonates. Pediatr Neonatol 2018; 59 (05) 464-473
• 21 Bergmann KR, Liu SX, Tian R. et al. Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol 2013; 182 (05) 1595-1606
• 22 Shiou S-R, Yu Y, Chen S. et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. J Biol Chem 2011; 286 (14) 12123-12132
• 23 Blackwood BP, Yuan CY, Wood DR, Nicolas JD, Grothaus JS, Hunter CJ. Probiotic Lactobacillus species strengthen intestinal barrier function and tight junction integrity in experimental necrotizing enterocolitis. J Probiotics Health 2017; 5 (01) 159